March 2006 in “Drug Discovery Today: Therapeutic Strategies”
The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
AI advancements, like AlphaFold, are speeding up drugdiscovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drugdiscovery, but emphasize waiting for clinical trial results.
The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.